Patents by Inventor Te-ik SOHN
Te-ik SOHN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932618Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: GrantFiled: March 13, 2023Date of Patent: March 19, 2024Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Patent number: 11827640Abstract: The present disclosure provides CFTR modulator and phosphodiesterase 4 (PDE4) inhibitor compounds of the formula (Ia): and compositions including said compounds. The compounds can provide functionality for modulating CFTR, methods for treating an eye disease or disorder, and methods for treating CFTR-related indications. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE4 in a biological system or biological sample, for treating an inflammatory disease or disorder, and for treating other PDE4-related indications. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: GrantFiled: October 22, 2021Date of Patent: November 28, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Myongjae Lee, Changmok Oh, Dami Lim, Kyeong-A Kim, Seolhee Lee, Ilji Jeong, Jaeeun Ryu, Jooyun Lee, Yearin Jun, Jinsun Kwon, Te-ik Sohn, Gunhee Kim, Jungho Kim, Jongmin Yoon, Jin Hee Lee, Hongchul Yoon, Jung Woo Lee, Joontae Park, Kyung Mi An
-
Publication number: 20230373954Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.Type: ApplicationFiled: August 1, 2023Publication date: November 23, 2023Inventors: Hong Chul Yoon, Joon Tae Park, Jung Woo Lee, Kyung Mi An, A Rang IM, Woo Jin Jeon, Jae Ho Heo, Chang Hee Hong, Jung Eun Park, Te Ik Sohn, Da Hae Hong, Jung Ho Kim, Jae Eui Shin, Yeong Ran Yoo, Min Whan Chang, In Gyu Je, Su Yeon Kang, Yoon Sung Song, Joo Yun Lee
-
Patent number: 11767311Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.Type: GrantFiled: June 16, 2021Date of Patent: September 26, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Hong Chul Yoon, Joon Tae Park, Jung Woo Lee, Kyung Mi An, Rang A Im, Woo Jin Jeon, Jae Ho Heo, Chang Hee Hong, Jung Eun Park, Te Ik Sohn, Da Hae Hong, Jung Ho Kim, Jae Eui Shin, Yeong Ran Yoo, Min Whan Chang, In Gyu Je, Su Yeon Kang, Yoon Sung Song, Joo Yun Lee
-
Publication number: 20230212140Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Inventors: Hong Chul Yoon, Kyung Mi, myong Jae Lee, Jin Hee Lee, Jeong-Geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230192650Abstract: The present invention provides a novel compound represented by Chemical Formula 2, or a pharmaceutically acceptable salt thereof. The novel compound according to the present invention exhibits an excellent acid secretion inhibitory effect.Type: ApplicationFiled: June 16, 2021Publication date: June 22, 2023Inventors: Hong Chul Yoon, Joon Tae Park, Jung Woo Lee, Kyung Mi An, Rang A IM, Woo Jin Jeon, Jae Ho Heo, Chang Hee Hong, Jung Eun Park, Te Ik Sohn, Da Hae Hong, Jung Ho Kim, Jae Eui Shin, Yeong Ran Yoo, Min Whan Chang, In Gyu Je, Su Yeon Kang, Yoon Sung Song, Joo Yun Lee
-
Patent number: 11643403Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: GrantFiled: November 13, 2020Date of Patent: May 9, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-Gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230080486Abstract: CFTR modulator compounds and compositions including said compounds are provided. The present disclosure also provides PDE4 inhibiting compounds and compositions including said compounds. Also provided are methods of using said compounds and compositions for modulating CFTR, methods for treating an eye disease or disorder and methods for treating CFTR-related indications. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE4, for treating an inflammatory disease or disorder and for treating other PDE4-related indications. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: ApplicationFiled: October 22, 2021Publication date: March 16, 2023Inventors: Myongjae Lee, Changmok Oh, Dami Lim, Kyeong-a Kim, Seolhee Lee, Ilji Jeong, Jaeeun Ryu, Jooyun Lee, Yearin Jun, Jinsun Kwon, Te-ik Sohn, Gunhee Kim, Jungho Kim, Jongmin Yoon, Jin Hee Lee, Hongchul Yoon, Jung Woo Lee, Joontae Park, Kyung Mi An
-
Publication number: 20230013143Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: November 13, 2020Publication date: January 19, 2023Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Publication number: 20230002348Abstract: The present invention provides novel compounds of chemical formula 1, optical isomers of the compounds, or a pharmaceutically acceptable salts of the compounds, or the optical isomers. The compounds, isomers, and salts exhibits excellent activity as GLP-1 receptor agonists. Particularly, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used therapeutic agents for metabolic diseases. In addition, they exhibits excellent pharmacological safety for cardiovascular systems.Type: ApplicationFiled: November 13, 2020Publication date: January 5, 2023Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-Gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
-
Patent number: 10590158Abstract: In one aspect, the present disclosure provides shishijimicin analogs of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, antibody drug conjugates of the compounds are also provided.Type: GrantFiled: June 29, 2016Date of Patent: March 17, 2020Assignee: WILLIAM MARSH RICE UNIVERSITYInventors: Kyriacos C. Nicolaou, Ruofan Li, Zhaoyong Lu, Te-ik Sohn, James Woods, Emmanouil N. Pitsinos
-
Publication number: 20180327439Abstract: In one aspect, the present disclosure provides shishijimicin analogs of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, antibody drug conjugates of the compounds are also provided.Type: ApplicationFiled: June 29, 2016Publication date: November 15, 2018Applicant: WILLIAM MARSH RICE UNIVERSITYInventors: Kyriacos C. NICOLAOU, Ruofan LI, Zhaoyong LU, Te-ik SOHN, James WOODS, Emmanouil N. PITSINOS